| 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid |
61260-15-9 |
C10H11O5P |
| (3R)-1-Methylpyrrolidin-3-amine |
457097-75-5 |
C5H12N2 |
| ETHYL 5-METHYL-1H-IMIDAZOLE-4-CARBOXYLATE |
51605-32-4 |
C7H10N2O2 |
| 3-Amino-4-chlorophenol |
16026-77-0 |
C6H6NOCl |
| 5,6-DIHYDROXYINDOLE |
3131-52-0 |
C8H7NO2 |
| Methyltrienolone |
965-93-5 |
C19H24O2 |
| Gefitinib |
184475-35-2 |
C22H24N4O3FCl |
| 2,4-Diamino-6-hydroxypyrimidine |
56-06-4 |
C4H6N4O |
| Poly (acrylic acid-co-hypophosphite) sodium salt |
1698-60-8 |
C10H8N3OCl |
| 2'-(Oxiranylmethoxy)-3-phenylpropiophenon |
22525-95-7 |
C18H18O3 |
| 4-Chloro-2-fluoroaniline |
57946-56-2 |
C6H5NFCl |
| Cefoperazone |
62893-19-0 |
C25H27N9O8S2 |
| Olopatadine hydrochloride |
140462-76-6 |
C21H23NO3.HCl |
| FLUTICASONE PROPIONATE |
80474-14-2 |
C25H31F3O5S |
| Mometasone furoate |
83919-23-7 |
C27H30Cl2O6 |
| GSK1349572sodiuMsalt;DOLUTEGRAVIRSODIUM;GSK1349572A;Dolutegravir sodiuM salt;Dolutegravir SodiuM ( API) |
1051375-19-9 |
C20H18N3O5F2-.Na+ |
| Dolutegravi;GSK1349572;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;S/GSK1349572(GSK1349572);Dolutegravir;GSK1349572(dolutegravir);S/GSK1349572 |
1051375-16-6 |
C20H19N3O5F2 |
| Chenodeoxycholic acid;URSODEOXYCHOLOCACID;3,7-dihydroxy-,(3-alpha,5-beta,7-alpha)-cholan-24-oicaci;3,7-dihydroxy-,(3alpha,5beta,7alpha)-cholan-24-oicaci;3,7-Dihydroxy-5-Cholanicacid;3-alpha,7-alpha-dihydroxy-5-beta-cholan-24-oicaci;3-alpha,7-alpha-dihydro |
474-25-9 |
2[C28H42N6O12S] |
| 9-Bromo-3-(2-Bromo Acetyl)-10,11-Dihydro-5H-dibenzo(c,g) Chromen-8(9H)-one |
1438383-89-1 |
C19H14O3Br2 |
| (5S)-N-(Methoxycarbonyl)-L-valyl-5-methyl-L-proline;(2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid;(2S,4S)-1-((R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidine-2-carboxylicacid;(5S)-N-(Methoxycarbonyl |
1335316-40-9 |
|
